Physician profile
Daniel J Carr
NPI 1497733992
$1,137.74
in general payments reported to CMS, 2019-2025
23 companies · $528 in 2025
The $528 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.28 · 2021: $112 · 2023: $98.88 · 2024: $358 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $907 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $906.72 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $251.50 | 2023-2025 | Venclexta |
| Lilly USA, LLC | $97.43 | 2021 | |
| Genzyme Corporation | $92.05 | 2025 | |
| Janssen Biotech, INC. | $77.99 | 2025 | Rybrevant |
| Glaxosmithkline, LLC. | $68.76 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Daiichi Sankyo INC. | $56.86 | 2023-2025 | Datroway, Enhertu |
| Novartis Pharmaceuticals Corporation | $56.00 | 2024-2025 | |
| Astellas Pharma US INC | $51.91 | 2023-2025 | Vyloy, Padcev |
| Eisai INC. | $48.17 | 2024-2025 | |
| Exelixis INC. | $41.28 | 2019 | |
| Pfizer INC. | $39.90 | 2024 | |
| Tersera Therapeutics LLC | $32.41 | 2025 | Zoladex |
| Astrazeneca Pharmaceuticals LP | $31.73 | 2025 | Lynparza |
| Stemline Therapeutics INC. | $26.49 | 2025 | Orserdu |
| Regeneron Healthcare Solutions, INC. | $23.78 | 2025 | Lynozyfic |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $21.93 | 2024 | |
| Beigene USA, INC. | $19.54 | 2023 | Brukinsa |
| Mirati Therapeutics, INC. | $18.80 | 2024 | Krazati |
| Alexion Pharmaceuticals, INC. | $18.19 | 2024 | Ultomiris |
| Celgene Corporation | $16.80 | 2024 | |
| Pharmaessentia USA Corporation | $16.59 | 2025 | Besremi |
| Taiho Oncology, INC. | $15.31 | 2024 | |
| Lsi Solutions INC | $14.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.